RxDoctor Payments Data

Lyubov Shkarupa

Psychiatric/Mental Health · Springfield, NJNPI 1881836443

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $8,458 of the $10,734 with a category attached, or 78.8%. 25 manufacturers reported payments, led by AbbVie at 39.5% of the total. Reporting peaked in 2023 at $4,520 and has fallen 72.2% since, to $1,256 in 2025. Among psychiatric/mental health clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$10,734in general payments, 2019–2025

Across 483 payments — averaging $22.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$4K
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$2K
  • Otsuka America Pharmaceutical, Inc.$941
  • Axsome Therapeutics, Inc.$807
  • Takeda Pharmaceuticals U.S.A., Inc.$429
  • Neurocrine Biosciences, Inc.$424
  • plus $2K from 19 others

What the payments were for

  • Speaking & faculty fees$2,20020%
  • Food & beverage$8,45879%
  • Education$761%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,734 in reported general payments places this provider in the 95th percentile of 1,212 psychiatric/mental health providers in New Jersey.

See all psychiatric/mental health providers in New Jersey

Most prescribed under Part D

DrugClaimsCost to plans & patients
Lisdexamfetamine Dimesylate11$2,397
Quetiapine Fumarate30$1,566
Zolpidem Tartrate ErZolpidem Tartrate12$1,243
Duloxetine Hcl22$1,112
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine19$1,047
Oxcarbazepine17$1,011
Bupropion XlBupropion Hcl66$805
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine14$566
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl11$514
Venlafaxine Hcl ErVenlafaxine Hcl21$493
Tranylcypromine Sulfate11$481
Doxepin Hcl25$462
Mirtazapine38$388
Haloperidol11$380
Alprazolam96$365

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Almatica Pharma LLCSertraline Hcl$249$4614 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,212 psychiatric/mental health providers in New Jersey.

Other psychiatric/mental health in Springfield

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →